Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - POINT Biopharma Global Inc. | tm217248d1_10k.htm |
| EX-4.2 - EXHIBIT 4.2 - POINT Biopharma Global Inc. | tm217248d1_ex4-2.htm |
| EX-31.2 - EXHIBIT 31.2 - POINT Biopharma Global Inc. | tm217248d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - POINT Biopharma Global Inc. | tm217248d1_ex31-1.htm |
| EX-32.1 - EXHIBIT 32.1 - POINT Biopharma Global Inc. | tm217248d1_ex32-1.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Matthew Hammond, Chief Financial Officer of Therapeutics Acquisition Corp. (the “Company”), hereby certify, that, to my knowledge:
| (1) | the Annual Report on Form 10-K for the year ended December 31, 2020 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 4, 2021
| /s/ Matthew Hammond | ||
| Name: | Matthew Hammond | |
| Title: | Chief Financial Officer | |